English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We previously identified a  TCR Vβ 21 T cell clone which was specific to CML patients, and demonstrated that  TCR Vα 13/ β 21 gene-modified CD3 +  T cells had specific cytotoxicity for HLA-A11 +  K562 cells. However, it remains unclear which antigen is specifically recognized by the  TCR Vβ 21 T cell clone. In this study, CD3 +  T cells from healthy donor peripheral blood were stimulated with the WT1 peptide or mixed BCR-ABL peptides in the presence or absence of IL-2 and IL-7. The distribution of the  TCR Vβ  repertoire was analyzed after different stimulations. We found that the mixed BCR-ABL peptides induced clonally expanded  Vβ 7–9- Dβ 2- Jβ 2–7 T cells while the Wilms Tumor 1 peptide induced clonally expanded  Vβ 11–2- Dβ 1- Jβ 1–1 T cells by high-throughput  TCRβ  sequencing and GeneScan. Interestingly, the sequence and CDR3 motif of  Vβ 11–2 T cell clone are similar to the  TCR Vβ 21 (a different  TCR V  region naming system) T cell clone that we previously found in CML patients. Thus, our findings suggest that the  TCR Vβ 21 T cell clone found in CML patients might be a T cell clone that specifically recognizes WT1.   Electronic supplementary material  The online version of this article (10.1186/s40364-019-0163-1) contains supplementary material, which is available to authorized users.

Identification of TCR Vβ11-2-Dβ1-Jβ1-1 T cell clone specific for WT1 peptides using high-throughput TCRβ gene sequencing